| Journal | Journal of sleep research |
| Study Type | Randomized Trial |
| Population | Human participants |
This is the first randomized controlled trial examining cannabinol (CBN) for clinically diagnosed insomnia disorder using objective sleep measurements. With limited evidence-based options for insomnia and widespread patient interest in cannabis-derived sleep aids, rigorous data on CBN’s actual efficacy fills a critical knowledge gap.
This double-blind, placebo-controlled crossover trial studied 20 adults with physician-diagnosed insomnia disorder, testing single doses of 30mg and 300mg cannabinol against placebo using polysomnography. The study measured wake after sleep onset (WASO) as the primary endpoint along with other objective sleep parameters. While the abstract is truncated, this represents the most rigorous clinical evaluation of CBN for sleep to date, using gold-standard methodology in a well-defined patient population. The crossover design with washout periods helps control for individual variability in sleep patterns.
“I’ve been cautious about recommending CBN given the lack of human clinical data, despite patient reports and market claims. This study finally provides the controlled evidence we need to evaluate whether CBN deserves a place in our insomnia treatment toolkit.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is cannabinol (CBN) and how does it differ from other cannabis compounds?
- How effective was CBN for treating insomnia in this study?
- What doses of CBN were tested and how were they administered?
- Who was included in this study and can the results apply to my patients?
- What safety considerations should clinicians know about CBN for insomnia?
FAQ
What is cannabinol (CBN) and how does it differ from other cannabis compounds?
Cannabinol (CBN) is an oxidative by-product of THC that forms when cannabis ages or is exposed to heat and light. Unlike THC, CBN is claimed to have sedating properties and may help with sleep, though this study represents the first rigorous clinical evaluation of these effects.
How effective was CBN for treating insomnia in this study?
This randomized, placebo-controlled crossover trial evaluated both 30mg and 300mg doses of CBN in 20 adults with physician-diagnosed insomnia disorder. The study measured objective sleep parameters using polysomnography, focusing on wake after sleep onset (WASO) as the primary outcome measure.
What doses of CBN were tested and how were they administered?
Participants received single oral doses of either 30mg (1.5%) or 300mg (15%) CBN in 2mL formulations, compared against matched placebo. Each participant tried all three conditions with a 2-week washout period between treatments in this crossover design.
Who was included in this study and can the results apply to my patients?
The study included 20 adults aged 25-65 with physician-diagnosed insomnia disorder meeting DSM-5 and ICSD-3 criteria, with Insomnia Severity Index scores โฅ15. The cohort was predominantly female (17 women, 3 men) with a mean age of 42 years, representing moderate to severe insomnia patients.
What safety considerations should clinicians know about CBN for insomnia?
All 20 participants completed the full protocol without dropout, suggesting good tolerability in this single-night study design. However, this was an acute treatment study, so longer-term safety data and potential drug interactions remain unknown and require further investigation.